CJC-1295 is a synthetic analog of growth hormone-releasing hormone, built on the GRF(1-29) fragment of human GHRH and developed by ConjuChem in the early 2000s. The published record describes a molecule that binds GHRH receptors on the anterior pituitary to stimulate the body's own growth hormone, with the long-acting DAC form extending its plasma half-life from minutes to roughly six to eight days by tethering to serum albumin. The honest bottom line up front: CJC-1295 holds no marketing approval for human therapeutic use in any major jurisdiction, its clinical development was discontinued, the human evidence is confined to early-phase pharmacokinetic studies, and it is encountered chiefly as a research chemical and within unregulated performance and anti-aging markets.
CJC-1295 is a synthetic GHRH analog whose DAC form sustains elevated growth hormone and IGF-1 for roughly six to eight days, and it is not an approved pharmaceutical for human use in any major jurisdiction.
The published chemistry describes CJC-1295 as a tetrasubstituted, thirty-residue synthetic peptide built on GRF(1-29), the biologically active N-terminal fragment of the 44-amino-acid human GHRH. Four targeted substitutions, reported in the patent literature from ConjuChem Biotechnologies, block the primary enzymatic cleavage sites and reduce oxidation and clearance, which is what gives the molecule its markedly greater metabolic stability over native GHRH.
CJC-1295 is a thirty-residue synthetic peptide carrying four amino acid substitutions on the GRF(1-29) backbone, administered by subcutaneous injection because, as a peptide rather than a small molecule, it is too large to be orally bioavailable in any practical sense.
Growth hormone-releasing hormone is a hypothalamic neuropeptide that travels through the hypophyseal portal circulation to the anterior pituitary, where it binds GHRH receptors on somatotroph cells and stimulates both the synthesis and the pulsatile secretion of growth hormone. Its action runs in opposition to somatostatin, and the balance between the two signals shapes the GH pulses that occur largely during slow-wave sleep. The reason CJC-1295 is built to mimic GHRH rather than replace GH directly is structural: acting upstream at the receptor preserves the downstream regulatory architecture of the axis, where the pituitary still gates output and IGF-1 feedback remains in play.
The first 29 residues, GRF(1-29), retain essentially full receptor-activating potency, which is why both sermorelin and CJC-1295 are built on that truncated active fragment rather than the full 44-amino-acid hormone.
The published mechanism describes CJC-1295 binding the same G-protein-coupled GHRH receptor that endogenous GHRH uses, coupling to the stimulatory G-protein and raising intracellular cyclic AMP through adenylate cyclase. That cascade activates protein kinase A and triggers calcium influx, which promotes both immediate exocytosis of stored growth hormone and increased transcription of the GH gene for replenishment. In practical terms the literature reports the peptide raising the amount of GH released per pulse and elevating mean GH and IGF-1 over time, rather than creating entirely new pulses on its own.
The DAC form's multi-day half-life maintains a continuous tonic stimulus at the receptor that elevates baseline GH and IGF-1 but flattens the natural pulsatile pattern, a departure from normal physiology that the literature treats as a point of scientific caution.
The Drug Affinity Complex is a bioconjugation strategy in which a reactive maleimidoproprionic acid group on the peptide forms a stable covalent thioether bond with the single free thiol on cysteine-34 of circulating serum albumin shortly after subcutaneous injection. Because albumin is one of the most abundant and long-lived proteins in plasma, the published rationale is that tethering the peptide to it creates a circulating depot, shielding the GHRH analog from the DPP-4 cleavage and rapid renal filtration that destroy native GHRH within minutes.
The albumin-tethered DAC conjugate persists with a plasma half-life reported in the range of roughly six to eight days, producing a continuous low-level stimulation of GH release across the dosing interval rather than discrete pulses.
The defining distinction the literature draws between the two forms is the presence or absence of the albumin-binding Drug Affinity Complex, and that single difference cascades through nearly every pharmacological property. A persistent source of confusion is terminology: the marketplace often labels modified GRF(1-29) as "CJC-1295 without DAC," which blurs two molecules that differ meaningfully in duration and release profile.
| Property | CJC-1295 with DAC | Modified GRF(1-29), no DAC |
|---|---|---|
| Duration of action | Roughly 6 to 8 days | About 30 minutes to a couple of hours |
| GH release pattern | Flattened, continuous "bleed effect" | Sharp, transient spike that decays quickly |
| Resemblance to natural pulses | Departs from pulsatility | More closely imitates physiologic rhythm |
| Reported dosing frequency | Historically far less frequent | More frequent, sometimes multiple times daily |
| Greater theoretical risk | Sustained, non-physiologic IGF-1 elevation | Lower, owing to rapid clearance |
Protocols aimed at preserving the body's natural pulsatile secretion favor the no-DAC modified GRF(1-29) form, which clears within about thirty minutes to a couple of hours, whereas the DAC form's multi-day persistence produces a flattened, continuous elevation of GH and IGF-1.
Growth hormone released under CJC-1295 stimulation travels to the liver and peripheral tissues, where it binds GH receptors and induces insulin-like growth factor 1, the principal mediator of many of GH's anabolic effects. The biologically important nuance reported in the literature is that the body normally signals through pulses, discrete bursts separated by troughs, a pattern that influences gene expression, fat metabolism, and tissue responses differently than a flat, continuous signal does. The DAC form produces precisely that flat signal, and this departure from physiologic pulsatility is central to the scientific caution about long-term consequences.
In early pharmacodynamic studies of the DAC form, single doses produced IGF-1 elevations that rose over the first several days and remained above baseline for one to two weeks, while documented observations stop at GH and IGF-1 concentrations themselves rather than clinical outcomes.
The peer-reviewed human evidence for CJC-1295 is thin and confined largely to early-phase pharmacology, sitting at the level of pharmacokinetic and pharmacodynamic measurement rather than clinical outcomes. The most cited work is a small randomized study from the mid-2000s showing that single subcutaneous doses of the DAC form produced dose-dependent, sustained increases in mean plasma GH and IGF-1 over roughly one to two weeks, establishing the long-acting profile but not therapeutic efficacy for any disease. The gap between what is documented, a peptide that reliably raises GH and IGF-1, and what marketing frequently claims, broad performance and longevity benefits, is wide and not bridged by rigorous human outcome data.
Most of what circulates about CJC-1295's effects derives from mechanism-based extrapolation, animal work, and anecdote rather than controlled clinical endpoints, and no published trials establish therapeutic efficacy for any disease.
The regulatory record is unambiguous: CJC-1295 holds no marketing approval as a therapeutic drug from the US Food and Drug Administration, the European Medicines Agency, or other major regulators, and it is not an authorized medicine for human use in those jurisdictions. Because it lacks approval yet is in demand, it is overwhelmingly sold by chemical suppliers under research-use-only or not-for-human-consumption labeling, a framing that sidesteps the requirements applying to medicines while shifting responsibility to the purchaser.
CJC-1295 is not an approved medicine for human use under the FDA, the EMA, or other major regulators, and it is prohibited at all times in sport under the World Anti-Doping Agency Prohibited List.
The safety picture for CJC-1295 is dominated as much by what is unknown as by what is documented, and the central structural point is that no long-term controlled human trials establish its safety, so the risk profile over months or years rests on extrapolation rather than evidence. Commonly reported short-term effects mirror GH-axis stimulation generally, while the more serious concerns are theoretical and attach to chronically raised IGF-1. A distinct, practical hazard arises from sourcing, since material sold as a research chemical is not manufactured or tested to pharmaceutical standards.
There are no long-term controlled human trials establishing the safety of CJC-1295, so its risk profile over months or years rests on extrapolation rather than evidence, which is itself a documented reason for caution.
Although these peptides are often grouped together as growth hormone secretagogues, the literature distinguishes two separate receptor systems: CJC-1295 and sermorelin are GHRH-receptor agonists, while ipamorelin is a ghrelin-receptor (GHSR) agonist that stimulates GH through a separate pathway and also suppresses somatostatin. Because the GHRH and ghrelin pathways are complementary rather than redundant, a GHRH analog like CJC-1295 is frequently paired with a ghrelin mimetic like ipamorelin in research and combination protocols to produce a synergistic GH release larger than either achieves alone.
| Criterion | CJC-1295 | Sermorelin | Ipamorelin |
|---|---|---|---|
| Receptor target | GHRH receptor | GHRH receptor | Ghrelin (GHSR) receptor |
| Backbone or class | GRF(1-29) plus substitutions, DAC optional | Unmodified GRF(1-29) fragment | Growth hormone-releasing peptide |
| Half-life | Days in the DAC form | Minutes | Short-acting |
| Regulatory standing | No approval; research chemical | Had a period of approved clinical use | No approval; research chemical |
CJC-1295 and sermorelin are GHRH-receptor agonists sharing the GRF(1-29) parentage while ipamorelin acts on the separate ghrelin receptor, and among the three, sermorelin notably had a period of approved clinical use, including as a diagnostic and pediatric agent.
Educational use only. This article describes what the published scientific and clinical literature reports about CJC-1295. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
